Topical pharmacologic therapy is the primary treatment for patients with primary open-angle glaucoma and ocular hypertension. However, in many patients multiple medications and different classes of drugs are often needed before there is adequate IOP control. After nearly a decade without new pharmacologic treatments, two new formulations were approved in late 2017. View this case-based webinar to learn how the latest treatments are helping to manage glaucoma.
This Educational Activity was made possible in part by a grant from Bausch + Lomb.Glaucoma Treatment: Tackling Real-World Cases
Media formats available:
Details
Presenters
Learning Objectives
Upon completion of this activity, the participant should be able to: - Explain how novel therapeutics differ in their methods of action from other topical medications.
- Evaluate the safety and efficacy of latanoprostene bunod for ocular hypertension and POAG.
- Describe how a healthy eye manages IOP in contrast with an unhealthy eye.
Accreditation
Accreditation Statement Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Evolve is an approved COPE Administrator. This course is COPE approved for 1 hour of CE Credit for Optometrists COPE Course ID: 63377-GL COPE Event ID: #117787 Faculty and Disclosures
DISCLOSURE POLICY
DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests:
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.- Inder Paul Singh, MD, and/or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Allergan plc., Alcon, Bausch + Lomb, Ellex, Glaukos, Ivantis, New World Medical, and Shire. Grant/Research Support: Ellex, Glaukos, and Sight Sciences.
- Constance Okeke, MD, MSCE, and/or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon, Allergan, Bausch + Lomb, Ellex, Glaukos, Medscape, Novartis, and Sight Sciences. Grant/ Research Support: Glaukos. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon, Bausch + Lomb, Ellex, Glaukos, Medscape, and NeoMedix.
- Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!